Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sales of Acorda's Ampyra Off To Strong Start

This article was originally published in The Pink Sheet Daily

Executive Summary

Because of a host of variables, estimating a peak sales figure based on actual demand has been tricky for analysts, but payers are covering the drug and patients are demanding it.

You may also be interested in...



Amid Uncertainties, Acorda Preps For Next Phase Of ACA: An Interview With Managed Markets Head Kent Rogers

With nine months to go before key aspects of the Affordable Care Act are implemented, Acorda Therapeutics’ head of managed markets, Kent Rogers, says he, like everyone, is ‘learning.” Acorda expects to have a game plan ready by mid-summer on how it will adapt its commercial strategy to ACA-initiated changes. Rogers also points out that the company may be less affected than others in the near term because Medicare already covers the majority of patients who take its multiple sclerosis drug Ampyra.

Novartis Gilenya Approved With Advisory Panel-Enhanced REMS

FDA follows the advice of its Peripheral and Central Nervous System Drugs Advisory Committee to ask doctors to do a range of testing and monitoring when they prescribe the MS drug.

Acorda Builds Ampyra Promotion On Years Of MS Outreach

Acorda's challenge in marketing its multiple sclerosis drug Ampyra is not that it is a new drug, but that it is a new drug indicated to treat an aspect of the disease that has never before been treated

Related Content

Topics

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel